Article Text

Download PDFPDF
Clinical utility of histopathology data: urological cancers
  1. Murali Varma1,
  2. Sean Williamson2
  1. 1 Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK
  2. 2 Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA
  1. Correspondence to Dr Murali Varma, Department of Cellular Pathology, University Hospital of Wales, Cardiff CF14 4XW, UK; MuraliCardiff{at}


Cancer datasets recommend standardised reporting of histopathological data items with elements categorised as either core (required) or non-core (recommended), irrespective of the clinical scenario. However, the clinical significance of a data item in an individual case would depend on the clinicopathological setting as well as local management guidelines. A data item that is critical for patient management in one clinical scenario may be largely irrelevant in another patient. Pathologists must understand how their data are used in clinical practice so that they can focus their limited resources appropriately. We briefly review the use of histopathological data in the management of urological cancers, highlighting scenarios where a data item may be of limited clinical utility.

  • prostate
  • urinary bladder
  • testis
  • kidney neoplasms
  • urologic neoplasms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Runjan Chetty.

  • Twitter @MuraliV72899596

  • Contributors Both authors have contributed equally to this review.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.